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Abstract:  The clostridial neurotoxin family consists of tetanus neurotoxin and seven 
distinct botulinum neurotoxins which cause the diseases tetanus and botulism. The extreme 
potency of these toxins primarily relies not only on their ability to specifically enter 
motoneurons but also on the activity their catalytic domains display inside presynaptic 
motoneuronal terminals. Subsequent to neurotoxin binding and endocytosis the catalytic 
domains become translocated across endosomal membranes and proteolyze unique peptide 
bonds of one of three soluble N-ethylmaleimide-sensitive fusion protein attachment 
receptors (SNAREs), vesicle associated membrane protein/synaptobrevin, synaptosome 
associated protein of 25 kDa, or syntaxin. As these substrate proteins are core components 
of the vesicular membrane fusion apparatus, cleavage of any of the substrate molecules 
results in the blockade of neurotransmitter release. This review summarizes the present 
knowledge about the molecular basis of the specific substrate recognition and cleavage 
mechanism and assesses the feasibility of reengineering catalytic domains to hydrolyze 
non-substrate members of the three SNARE families in order to expand the therapeutic 
application of botulinum neurotoxins. 
Keywords:  botulinum neurotoxin; tetanus toxin; SNARE; zinc protease; enzyme 
engineering 
 
 
OPEN ACCESSToxins 2010, 2                    
 
 
666
1. Introduction 
Clostridial neurotoxins (CNT), a family of closely related bacterial protein toxins, consist of seven 
antigenically distinguishable botulinum neurotoxins (BoNTs) and tetanus neurotoxin (TeNT). Each 
CNT is synthesized as a ~150 kDa single chain protein, but subsequently cleaved by specific 
clostridial or host proteases. Cleavage results in an N-terminal ~50 kDa light chain (LC) and a   
C-terminal ~100 kDa heavy chain (HC). Both chains remain attached via a single disulfide bond 
formed between cysteines at the C-terminus of the LC and the N-terminus of the HC, a peptide loop 
formed by the N-terminal ~55 amino acids of HC that wraps around the LC and further non-covalent 
interactions (Figure 1). The HC comprises two subunits, a largely α-helical domain of ~50 kDa at the 
N-terminus, designated HN, and a ~50 kDa fragment at the C-terminus, HC, which is composed of two 
~25 kDa domains, a lectin like jelly role domain HCN and a β-trefoil domain HCC (Figure 1). 
Figure 1. Structure of CNTs. Ribbon representation of BoNT/A. The catalytic (L), 
translocation (HN), and binding domains (HC; consisting of HCC and HCN) are specified. 
The HN domain derived loop wrapping around the LC (L) is colored orange. 
 
 
Poisoning by BoNTs mainly occurs upon oral ingestion and toxin uptake at intestinal epithelial 
cells, whereas TeNT is produced and released into the circulation by bacteria that germinate in 
infected tissue lesions. Eventually CNTs reach cholinergic motor nerve terminals, where a four step 
process is initiated that ultimately renders a synapse inoperative. In order that they can be taken up via 
the recycling pathway of synaptic vesicles (SV), they first bind to complex gangliosides at the surface 
of nonmyelinated nerve terminals [1]. Requisite for the second step, the endocytosis, is the binding of 
the toxin to an additional receptor. In case of BoNTs this may generally be an intravesicular portion of 
a synaptic vesicle transmembrane protein, which becomes transiently exposed on the nerve cell surface 
during the course of exo- and endocytosis. Recent work had demonstrated that synaptotagmin (Syt)-I Toxins 2010, 2                    
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and Syt-II act as protein receptors for BoNT/B and G [2–5] and the synaptic vesicle protein (SV) 2 as 
receptor for BoNT/A and E [6–8], and possibly also BoNT/F [9,10]. Protein receptors have not yet 
been determined for BoNT/C and D as well as TeNT. The interaction with a ganglioside and the 
respective protein receptor appears to be mediated by HCC as demonstrated for TeNT and several 
BoNTs. In contrast, the role of the HCN-domain is still unresolved, although low affinity binding to 
lipidic membrane components was recently reported for BoNT/A HCN  [11]. Intracellular transport 
subsequent to endocytosis proceeds differently for BoNTs and TeNT. TeNT obviously harnesses a 
particular protein receptor that directs this toxin to the transcytosis pathway instead of the SV 
recycling pathway carrying it into the spinal cord, where it has to repeat the first two steps of the four 
step mechanism of action. Whether in a cholinergic nerve terminal or in a neuron of the spinal cord, 
next the toxins become exposed to an acidic environment during transport of the endocytosed vesicle 
which initiates the third step. Acidification triggers a structural rearrangement in HN and the formation 
of a cation selective channel. This is probably coupled to partial unfolding of the LC, its entry into and 
transit through the HN channel followed by its refolding in the cytosol [12,13]. Subsequent to reduction 
of the disulfide bridge the LC is released from the HC. Once in the cytosol the LCs exert their catalytic 
activity, the molecular mechanisms of which will be discussed in the following sections, and 
proteolyze core components of the vesicular membrane fusion apparatus. Substrate cleavage leads to a 
blockade of neurotransmitter release, but to different clinical symptoms for BoNTs versus TeNT. 
BoNTs act inside the motoneuron and thus cause flaccid paralysis, which can result in respiratory 
failure and death. TeNT poisons inhibitory interneurons to cause just opposite symptoms, spastic 
paralysis [14]. 
CNTs are regarded as the most hazardous natural substances known. The 50% lethal doses for 
susceptible mammals including man amount to approximately one nanogram per kg of body 
weight [15]. Due to the lack of immunization protection in the population, BoNTs also represent a 
major bioweapon [16,17]. On the other hand, BoNT/A and B have become widely used therapeutics 
for the treatment of a variety of neurological disorders with still increasing numbers of indications 
during the past two decades [18]. 
2. Cleavage of SNAREs 
The intracellular mode of action of the neurotoxins was discovered in the early 1990s, initiated by 
the identification of the Zn
2+ binding motif, His-Glu-X-X-His, in the primary sequence of TeNT [19] 
and its conservation in the amino acid sequence of BoNT/A [20,21]. Evidence for a zinc dependent 
proteolytic mode of action was provided via the demonstration of zinc binding for BoNTs [22] and the 
abolishment of TeNT evoked blockade of neurotransmitter release by classical zinc endoprotease 
inhibitors [23]. Shortly after, selective searches for substrates among synaptic vesicle proteins led to 
the identification of the integral synaptic vesicle membrane protein VAMP (vesicle associated 
membrane protein), also termed synaptobrevin, as target for BoNT/B and TeNT [24–26]. BoNT/D, F, 
and G were subsequently also shown to cleave VAMP/synaptobrevin [27–29]. However, except for 
TeNT and BoNT/B, the toxins hydrolyze different peptide bonds. BoNT/D and F cut the neighboring 
bonds Gln58-Lys59 and Lys59-Leu60, respectively, almost in the middle of the 116-amino acid sized 
VAMP/synaptobrevin-2, whereas the scissile bond for BoNT/B and TeNT is located 17 amino acids Toxins 2010, 2                    
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further downstream and that for BoNT/G shifted by additional five residues towards the C-terminal 
transmembrane domain (Figure 2; [25,27–29]). The proteolytic activity of the remaining CNTs was 
found to be directed against proteins of the presynaptic membrane. BoNT/A, C, and E proteolyze 
SNAP-25 (synaptosomal associated protein of 25 kDa) [27,30–33]. Again different peptide bonds are 
attacked. BoNT/A and C hydrolyze neighboring bonds, 9 or 8 amino acids, respectively, away from 
the  C-terminus of this 206 residues comprising protein, while BoNT/E cleavage releases the 26   
C-terminal residues [34–36]. The substrate specificity of BoNT/C turned out to be unique, since yet 
another protein of the presynaptic membrane, syntaxin, had already been identified as substrate [37–39]. 
The hydrolysable peptide bond, Lys253-Ala254, is again located in the C-terminal region, 12 amino 
acids upstream of the C-terminal transmembrane domain (Figure 2; [40]). 
Figure 2. Schematic drawing of the substrates of CNTs and specification of the individual 
cleavage sites. Syntaxin 1A (top) is a type II membrane protein that contains four -helical 
regions. The C-terminal  -helical region is involved in SNARE complex formation. 
Synaptosome associated protein of 25 kDa (SNAP-25, middle) is anchored in the plasma 
membrane via palmitoyl groups that are attached to cysteine residues in the middle of the 
molecule. Both its -helical segments become constituent parts of the SNARE complex in the 
course of membrane fusion. Vesicle associated membrane protein (VAMP)/Synaptobrevin-2 
(bottom), a type II membrane protein of synaptic vesicles, completes the coiled-coil four 
helix SNARE bundle complex via inclusion of its central -helical region to the other three 
helices. The individual peptide bonds hydrolyzed by CNTs are indicated by arrow heads 
below the primary structure sections and the N-terminal amino acid positions are specified. 
The substrate positions (P3 to P3’) around the scissile peptide bond as defined by Schechter 
and Berger [89] are shown above the primary structure section of Syntaxin 1A. 
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The CNT substrate proteins are members of larger protein families that are collectively termed 
SNAREs (soluble N-ethylmaleimide-sensitive factor attachment protein receptors). A common feature 
of all SNAREs is the presence of one (or as an exception two) -helical domain(s) of ~70 amino acids, 
the SNARE motif, endowed with the capacity to form coiled-coils. Sets of SNAREs generally build 
the core for the individual intracellular membrane fusion processes and zippering of such sets of 
SNAREs via their SNARE motifs into parallel four-helix coiled-coil bundles is regarded to provide the 
driving force for membrane fusion [41,42]. E.g., the mammalian syntaxin 1A, SNAP-25 (comprising 
two SNARE domains), and VAMP/synaptobrevin-2 are the nerve terminal SNAREs and mediate 
neurotransmitter release into the synaptic cleft. Consequently, their cleavage results in the blockade of 
neurotransmission. 
Studies about the susceptibility of other mammalian SNAREs toward CNTs revealed that the 
majority is not hydrolysable. In addition to the established substrates, merely VAMP/synaptobrevin-1, 
cellubrevin/VAMP-3, syntaxin 2, syntaxin 3, and the murine SNAP-23 proved to be substrates for the 
respective CNT serotypes (reviewed in [43]). Susceptibility at least at high LC concentrations can be 
conferred to some non-substrate SNAREs by replacements of one or two crucial amino 
acids [36,44,45]. 
3. Catalytic Mechanism 
The mode of Zn
2+-coordination classifies the LCs of CNTs into the gluzincin superfamily among 
the clan MA of metalloproteases [46,47]. As a characteristic feature of this superfamily, Zn
2+ is 
coordinated by two histidine residues of the His-Glu-X-X-His motif, a water molecule, which is 
bonded to the glutamate residue of the motif, and another glutamic acid residue located about   
35 residues downstream in the primary structure. Searches for proteins exhibiting a related tertiary 
structure revealed that the central portion is structurally similar to a portion of the zinc metalloprotease 
thermolysin [48]. These similarities are limited to the helix containing the His-Glu-X-X-His motif and 
a four-stranded -sheet buttressing the helix. The loop regions connecting the conserved secondary 
structure elements of the catalytic core are drastically expanded compared to those of thermolysin. In 
addition, the CNT catalytic core is not involved in substrate binding via side-chain side-chain 
interactions. Substrate specificity is thus imparted by distinct amino- and carboxyl-terminal structural 
elements flanking the core, which appear to be structurally unique to the CNTs [49], as they contain 
substrate-binding sites (see below; [50]). 
As thermolysin represents the well characterized prototypical member of the gluzincin 
metalloprotease superfamily, its mode of peptide bond cleavage is presumably to a large extent similar 
to that of CNTs. In case of thermolysin, catalysis follows a general base-type mechanism [51]. It was 
proposed that the water molecule is polarized via its interaction with Zn
2+ and the glutamic acid 
carboxylate group of the His-Glu-X-X-His-motif and can thereby nucleophilically attack the carbonyl 
carbon of the scissile peptide bond to form an oxyanion. Simultaneously, a proton abstracted from the 
attacking water is shuttled via the carboxyl group of the glutamate to the scissile peptide bond 
nitrogen, and the glutamate may then stabilize the tetrahedral intermediate by forming a salt bridge 
with the positively charged amide nitrogen. The negative charge that develops on the carbonyl oxygen 
atom in the tetrahedral transition state is stabilized by hydrogen bonding interactions with a protonated Toxins 2010, 2                    
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histidine (position 231) and the hydroxyl group of a tyrosine (position 157). It is assumed that His-231 
is retained in proper position and protonated state through a hydrogen bonding interaction with an 
aspartate (position 226). The protonated amide nitrogen then facilitates C-N-bond disruption and may 
subsequently receive a second proton derived from the water, possibly again mediated by the glutamic 
acid carboxylate group [51,52]. 
The available data on CNTs support a similar mechanism (Figure 3). In fact, the nucleophilic attack of 
the scissile bond carbonyl carbon by the coordinated polarized water molecule as well as the subsequent 
relocation of a proton from the attacking water to the scissile peptide bond nitrogen may be ascribed to 
the action of glutamate of the His-Glu-X-X-His motif as its mutation leads to complete deactivation of 
the catalytic activity of e.g., BoNT/A  [53] and BoNT/E  [54]. It has also been discussed that a 
conserved tyrosine serves as proton donor for the amide nitrogen. If this was true, one would expect a 
much more severe effect on the hydrolytic activity by its replacement by phenylalanine (see below). 
Primary structure alignments of all eight CNTs revealed three conserved residues within the 
otherwise less conserved region around the zinc coordinating residues of the LCs, i.e., a glutamate, an 
arginine, and a tyrosine (Figure 3).  
Figure 3. Proposed hydrolytic mechanism of BoNT/A. In the first step, a water molecule 
polarized by Glu223 and Zn
2+, nucleophilically attacks the carbonyl carbon of the scissile 
peptide bond to form an oxyanion. The side chain of Tyr365 is responsible for the 
stabilization of the negative charge that develops in the tetrahedral transition state on the 
carbonyl carbon atom. For Arg362 the scenario that proposes interactions between its 
guanidino group and the carbonyl oxygen of the P1’ amino acid is depicted. Glu350 likely 
keeps Arg362 and His222 in proper position through ionic interactions. Peptide bond 
cleavage is likely achieved by two proton transfers from the attacking water mediated by 
the carboxyl group of Glu223 and results in a protonated amine. The nomenclature used for 
substrate amino acids is according to Schechter and Berger [89]. 
 
 
They reside ~120 amino acids downstream from the His-Glu-X-X-His motif and are separated by 
11 and 2 amino acids, respectively. Two recently solved crystal structures of LC/A and LC/E bound to 
non-cleavable short SNAP-25 peptides comprising the respective scissile bonds showed that this Toxins 2010, 2                    
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tyrosine (position 365 and 350 in LCA and LCE, respectively) lines up in close proximity to the 
scissile peptide bond [55,56] and might therefore be the functionally equivalent residue to Tyr-157 of 
thermolysin. Its central role in substrate cleavage was demonstrated for TeNT (position 374) and 
BoNT/A and E. In BoNT/A and TeNT the substitution with phenylalanine drastically decreased the 
hydrolytic activity [57,58]. Kinetic analyses for BoNT/A-Y365F revealed a substantial reduction of 
kcat, while Zn
2+-binding and substrate binding were not significantly affected [57,59]. This finding was 
interpreted as participation of its side group in the stabilization of the transition state oxyanion [57] 
and was later on also evidenced by structural studies [56,60]. Substitution of tyrosine with alanine 
even abolished the enzymatic activity of BoNT/E and TeNT [58,61]. The stronger effect caused by the 
mutation to alanine might be due to additional important interactions such as interaction of the benzene 
ring with the P2’ (for explanation see Figure 2) carbonyl group in case of BoNT/E [55]. 
The counterpart of the thermolysin His-231 might be the above mentioned strictly conserved 
arginine (position 362 and 347 in LCA and LCE, respectively). Its replacement in BoNT/A by various 
residues and by alanine in BoNT/E generally led to an approx. 100-fold decrease in kcat, while KM 
remained unaffected [57,59,61]. The difference in free energy for transition state binding of mutated 
vs. wild-type LCA as well as the guanidino group positioning in the vicinity of the scissile peptide 
bond led to the suggestion that this residue might also be involved in oxyanion binding in the 
transition state  [57,60]. Alternatively, recently determined co-crystal structures of LC/A and LC/E 
bound to short non-cleavable SNAP-25 derived peptides suggested an H-bond interaction between the 
Arg362 guanidino group and the carbonyl oxygen of the P1’ position [55,56]. 
CNTs presumably also possess an analog to Asp-226 of thermolysin. A glutamate, the third of the 
above mentioned strictly conserved residues in the vicinity of the zinc coordinating residues, occupies 
a similar position in all CNTs  [62]. Removal of its negative charge dramatically diminished the 
hydrolytic activity of BoNT/A and E  [57,61]. Beside a corresponding role in securing the proper 
positioning and the protonated state of the guanidino group of the conserved arginine it adds to the 
negative electrostatic potential and, at variance with thermolysin, it appears to be important for 
orienting one of the Zn
2+ coordinating histidines at the active site [57,61]. 
4. Mode of Substrate Recognition 
CNTs display unique substrate selectivity in contrast to the broad specificity of conventional 
proteases. Initial studies employing various sized peptides comprising the individual cleavage sites 
revealed that extended substrate sections of about 30 amino acids are required for optimal catalytic 
activity of VAMP/synaptobrevin-2 cleaving  [29,63–67] and SNAP-25 cleaving  [36,68] CNTs. 
Furthermore, the substrate-length requirements varied with the CNT serotype. For example, BoNT/B 
and TeNT, although hydrolyzing the identical peptide bond, were shown to be dependent upon 
different sized (40 and 62 residues, respectively) peptides [64]. Complementary cleavage studies on 
substrate point mutants indicated that the enzymatic activity of all CNTs is dependent upon substrate 
interactions remote from the cleavage site and thus not upon structural constraints   
[36,45,62,67,69–72]. Since that time the involvement of each VAMP/synaptobrevin-2 and SNAP-25 
residue in LC binding has been analyzed by systematic approaches for all LC serotypes but BoNT/G 
and C [44,73]. The collected results verified the above mentioned findings and led to an in-depth map Toxins 2010, 2                    
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of crucial substrate residues and provided evidence for the resistance of SNARE isoforms like human 
SNAP-23 or TI-VAMP/VAMP-7 versus CNTs (Figure 4B). 
Figure 4. Substrate recognition of CNTs. (a) Cartoon illustration of the mode of substrate 
binding of LCA and LCF.  Superposition of ribbon diagrams of LCA (gray)  bound to 
SNAP-25 (residues 152-202; green) and LCF (tan) bound to VAMP/synaptobrevin-2 
(residues 32-58; red). (b) Individual substrate requirements of LCs. Amino acid sequences 
of VAMP-2 and TI-VAMP (lower panel) as well as those of rat SNAP-25 and human 
SNAP-23 (upper panel) were aligned. The scissile bonds of LCs are indicated by arrow 
heads. Conserved residues are depicted by gray boxes in the sequence of SNAP-23 and  
TI-VAMP, whereas similar residues are given by open boxes. Residues shown in red, 
orange, or yellow boxes in separate lines for the various LCs indicate that removal of their 
side group decreases cleavage by the respective LC (given left) by more than 75%, 50%, or 
25%, respectively. Residues highlighted by circles using the same color code depict to 
what extent introduction or reversal of charges affects cleavage. Data from the following 
publications were incorporated into this scheme:  [44,65,70,73,81,90–93]. In case of 
divergent data on mutants, averaged values are shown. 
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The recognition model involving substrate/enzyme interactions remote from the active site proved 
to be compatible with crystal structure data obtained for a catalytically inactive BoNT/A LC bound to 
the carboxyl terminal half (residues 141-204) of SNAP-25 [50]. The co-crystal revealed an extensive 
interface between protease and substrate. The SNAP-25 segment Gln152 to Met202 was found to wrap 
around most of the LC’s periphery (Figure 4A), and 19 amino acids thereof were proposed to establish 
side-chain/side-chain contacts with the protease distributed along the whole interface. It is feasible that 
SNAP-25 binding initiates at the most distal 21-residue segment (known as the α-exosite), which 
forms a distorted α-helix, and is followed by the formation of successive additional interactions via 
anchor points that together direct the path of the substrate into the LC’s active site [50]. A comparison 
of LC structures in their free and substrate bound states provided evidence that regions near the active 
site cavity underwent structural rearrangements on substrate interaction. In particular, the loop around 
amino acid position 250 switches from an open to a closed conformation in order to facilitate substrate 
binding at the catalytic centre [50]. These data argue for an induced fit recognition mechanism for 
BoNT/A. The extraordinary substrate specificity of CNTs may thus be explained by the requirement 
for remote interaction sites and their proper spatial relationship to the specific cleavage site. 
The co-crystal structure of LCA bound to SNAP-25 does not allow for the definition of the LC 
pockets involved in the binding of substrate residues near the scissile bond, as a double mutant of the 
active site was used to render the enzyme inactive  [50]. A number of recently solved co-crystal 
structures and docking studies for LCA with small-molecule inhibitors [74,75] and SNAP-25 derived 
peptides [56,60,76–78] contributed to fill this information gap. In particular, crystals of LCA bound to 
non-cleavable six-residue SNAP-25 peptides, one containing Gln197-Arg-Ala-Thr-Lys-Met202, 
whereas the authentic P1 Gln-197 was replaced with arginine in the second peptide, allowed for the 
unequivocal definition of the pockets S1-S5’ [56]. The importance of several of these suggested LC 
pocket forming amino acids was corroborated in parallel studies by enzymatic characterization of LC 
mutants [59,79]. Similar information about interactions at the active site has also been collected for LCE. 
Here, a co-crystal structure of the non-cleavable four-residue SNAP-25 peptide, Arg180-Ile-Met-Glu183, 
that represents P1-P3’, could be solved and the LC residues of the S1-S3’ pockets be delineated [55]. 
The LCE residues forming the S1’ and S2’ pockets had been suggested earlier based on the enzymatic 
characterization of LCE mutants  [80]. Moreover, in the latter study, LC residues representing 
constituents of the S2 and S3 pockets have also been suggested. 
Structure data about the mode of VAMP/synaptobrevin-2 recognition by LCF have recently also 
been achieved [81]. In this case, the co-crystallization of two, 37- and 32-residue, VAMP mimicking 
peptide inhibitors ending in D-cysteine instead of Gln-58 at the P1 position succeeded. The direction 
of substrate binding was found to be similar to that of thermolysin and to those observed for SNAP-25 
peptides and LCA and LCE. The paths how the inhibitors bind along the LCF surface are basically 
similar to that of SNAP-25 on LCA, though loops protrude differently. In addition, 
VAMP/synaptobrevin-2 exhibits each one short segment of β-sheet and α-helix conformation, whereas 
SNAP-25 is extended in the entire matchable area (residues 168–197). However, the SNAP-25/LCA 
interface is longer; a 21-residue distorted α-helix (residues 147–167) joins in N-terminal direction and 
forms major interactions with LCA (Figure 4A;  [50]). Like the SNAP-25/LCA interaction,   
side-chain/side-chain amino acids contacts between VAMP/synaptobrevin-2 and LCF are suggested to 
exist along the whole interface. Cleavage studies using mutants confirmed the importance of some of Toxins 2010, 2                    
 
 
674
the LC and substrate residues and underscored that contacts remote from the scissile bond are critical 
for an efficient substrate recognition process  [44,81]. Thus, the course of VAMP/synaptobrevin-2 
binding by LCF might occur similarly to that outlined for SNAP-25 and LCA. Due to the nature of the 
LCF inhibitors used, the co-crystal structure, however, does not provide information about interactions 
taking place downstream from the P1 site. Results of cleavage studies that employed mutated 
VAMP/synaptobrevin-2 also coincide with a similar recognition mechanism, as the P1’-P2’ residues 
proved to be important for substrate cleavage, whereas residues located further downstream probably 
do not contribute or are far less critical for substrate recognition (Figure 4B; [44,65,67,70]). 
Superposition of the substrate-free LCF structure onto the LCF-VAMP/synaptobrevin-2 structure 
led to the detection of major side chain rotamer variation around the active site. These facilitate proper 
substrate binding by opening the active site and allow for salt bridges with the P3 and P2 residues [81]. 
The steric changes in LCF upon substrate binding are also compatible with an induced fit recognition 
mechanism as proposed for BoNT/A. 
5. Reengineered CNT Catalytic Domains to Target Non-substrate SNAREs 
Twenty years ago BoNTs became an approved therapeutic for the treatment of the neurological 
disorders strabismus, blepharospasm, and hemifacial spasm. Since then their application range steadily 
increased and includes today further medical conditions like axillary hyperhydrosis or even cosmetic 
use. However, the clinical application of BoNTs is restricted to disorders that rely on hyperactivity of 
cholinergic neurons, due to the toxins’ tropism for these neurons and the preferential cleavage of 
neuronal SNAREs. 
These limitations can now probably be bypassed, owing to the elucidation of the molecular 
structure of BoNTs and the increasing information about structure-function relationships. 
Consequently, attempts were undertaken to retarget BoNT activity to specific neurons or non-neuronal 
cells by replacing their cell binding subunit, HC. For example, the Erythrina cristagalli lectin, 
selectively recognizing galactose containing carbohydrates as present on nociceptive afferents, was 
chemically conjugated to purified L-HN of BoNT/A. This conjugate was shown to affect nociceptive 
neurons, which opens up the possibility to develop retargeted BoNTs for the treatment of chronic 
pain [82,83]. Furthermore, a fully recombinant fusion protein consisting of L-HN of BoNT/C and the 
epidermal growth factor was designed. This construct was reported to inhibit mucin secretion from the 
human respiratory epithelial cell line A549 and might thus have the potential to treat mucus 
hypersecretion in asthma and chronic obstructive pulmonary disease  [84]. The latter example 
demonstrates that the intracellular action of BoNTs can in principle be harnessed to interfere with 
therapeutically relevant release processes of non-neuronal cells. However, if the release process is 
driven by SNAREs that are not susceptible, the LC has to be reengineered in order to be able to attack 
the desired SNARE. 
Such a re-targeting has recently been achieved for LCE. Its enzymatic activity could be extended to 
human SNAP-23 by a single amino acid replacement [85]. Within the identified interacting segment of 
the natural substrate human SNAP-25, Met167-Asp186 [73], human SNAP-23 differs in six amino 
acids (Figure 4B). The exchange of Asp179 by Lys185 in the P2 position of SNAP-25 had been 
recognized to be most critical for cleavage by BoNT/E [36,73], probably because it forms a salt bridge Toxins 2010, 2                    
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with Lys224 of the respective LCE S2 pocket [80]. Consequently, the resistance of human SNAP-23 
might predominantly be due to repulsion of the P2 residue Lys185. Chen and Barbieri therefore 
replaced the LCE S2 pocket residue Lys224 with aspartic acid. In vitro cleavage assays showed that 
the mutated LCE exhibited a hydrolysis rate in the range of SNAP-25 cleavage by wild-type LCE 
versus the otherwise non-cleavable human SNAP-23; KM/kcat was nine-fold reduced [85]. Furthermore, 
LCE-Lys224Asp decreased IL-8 and mucin secretion in TGF-α stimulated HeLA cells [85]. 
BoNT/A is currently the most attractive CNT serotype in terms of medical application, due to its 
pronounced longevity versus other BoNTs and the existing practice of its handling. It appears feasible 
that LCA could also be re-targeted to human SNAP-23. Promising starting points are an enlargement 
of or/and introduction of a negatively charged side group into the S3’ pocket to accommodate the 
SNAP-23 P3’ Lys206, or to adapt the hydrophobic S5’ pocket for the exchange of SNAP-25 Met202 
by Leu208 in SNAP-23 (Figure 5; [50,56]). In addition, as compensation for the lost important salt 
bridge between Arg176 and LCA Glu148, likely constituting a major anchor point for the progress of 
SNAP-25 binding, new salt bridges might be generated at other positions, e.g., by replacing Val304 or 
Ser143 with aspartic acid to form salt bridges with hSNAP-23 Lys185 and Arg186, respectively. 
Figure 5. Mode of substrate recognition in selected LC binding pockets. Stick 
representations of LC (gray) and substrate (green) amino acid residues in their steric 
configuration at selected binding pockets. Amino acid variations between established 
substrates and non-cleavable isoforms are depicted by amino acid alignments. Scissile 
bonds for LCF and LCA are indicated by arrowheads. (a) VAMP/synaptobrevin-2 binding 
by LCF at two selected binding sites, whose configuration might contribute to inefficient 
TI-VAMP interaction. (b) SNAP-25 binding by LCA at two elected binding sites, whose 
configuration might contribute to inefficient hSNAP-23 interaction. 
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The non-cleavable TI-VAMP ([86]; also called VAMP-7) might also be an interesting target. It is 
known to be involved in processes mediating neurite outgrowth, synaptic transmission, plasma 
membrane remodelling, and lysosomal secretion (reviewed in [87]). Based on already available data 
(see above), adaptation in LCF could be conducted to endow it with specificity for this SNARE. The 
removal of the negative charge of Glu315 or/and Glu310 might avoid charge dependent repulsion by 
TI-VAMP Asp124 and Glu128, respectively. Likewise, exchange of Arg133 might eliminate 
interference with TI-VAMP Lys137 (Figure 5). Enlargement of the LCF S1’ pocket, by means of two 
glutamic acid to aspartic acid substitutions could facilitate P1’ interaction with Arg153, the 
corresponding residue of VAMP-2 Lys59. However, “high throughput” screening systems are 
certainly required, in particular if LC pockets must be restructured fundamentally involving 
simultaneously mutations of several amino acids. Possibly, yeast is suitable for screening of LC 
mutants, as exemplified recently for a viral protease [88]. 
If LC re-targeting succeeded one may wish that the re-targeted LC loses its activity versus the 
original substrate, in case that the original and the new substrate are co-expressed in the desired target 
cell. Therefore, in addition to mutations which enable cleavage of the new substrate, LC amino acids 
must be identified and replaced whose mutations exclusively impair cleavage of the original substrate. 
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